लोड हो रहा है...
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
BACKGROUND: Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial sit...
में बचाया:
में प्रकाशित: | BMC Cancer |
---|---|
मुख्य लेखकों: | , , , , , , , , , , , , , , , , , , , , , , , , , |
स्वरूप: | Artigo |
भाषा: | Inglês |
प्रकाशित: |
BioMed Central
2020
|
विषय: | |
ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7656772/ https://ncbi.nlm.nih.gov/pubmed/33176725 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07546-1 |
टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|